INTRODUCTION
Primary cutaneous lymphomas consist of T cell, B cell and natural killer cell neoplasms [1 && ]. Cutaneous T-cell lymphomas (CTCLs) include many types of T-cell lymphomas. Mycosis fungoides and Sézary syndrome are the most common types and often synonymously named CTCL. They are characterized by malignant T cells homing to the skin. The neoplastic T cells usually contain a CD4 þ and CD8 ]. CD47 is ubiquitously expressed; it functions as a 'marker of self' on erythrocytes and other cells in order for the innate immune system (e.g. macrophages and dendritic cells) to recognize a host cell from foreign (e.g. microorganisms) [6] ]. Earlier studies show an increase in the antiphagocytic CD47 protein expression on dysplastic human hematopoietic cells, particularly in acute myelogenous leukemia (AML) and in chronic myeloid leukemia, and inhibits phagocytosis of these cells through CD47-SIRPa interactions allowing evasion of immunosurveillance [7] [8] [9] . It was found that there is a direct correlation with immune evasion and poor prognosis in patients with leukemia, non-Hodgkin lymphoma (NHL), bladder and breast carcinomas [4
. Increased CD47 mRNA expression in multiple NHL subtypes independently predicted adverse clinical outcomes, particularly in diffuse large B-cell lymphoma, B-cell chronic lymphocytic leukemia and mantle cell lymphoma [11] . Increased expression of CD47 is also a poor prognostic factor when found on solid tumors, such as ovarian, breast, colon, bladder, prostate, glioblastoma and hepatocellular carcinomas [12] . In breast cancer studies, specific breast cancer subtypes have CD47-associated superenhancers (long stretches of DNA) that induce overexpression of CD47, enabling its growth and spread [13 & ]. Recent research found that high levels of CD47 are not only expressed in CTCL, but also on fibroblasts following activation of transcription factor cJun contributing to the development of diseases such as idiopathic pulmonary fibrosis and scleroderma [14 & ]. Atherosclerosis is another disease process involving the upregulation of CD47, compared to nonatherosclerotic vascular tissue, suggesting a pathological commonality in both cancer and cardiovascular disease [15] . CD47 targets and binds to SIRPa on the surface of myeloid cells and elicits a 'do not eat me' signal; blocking this interaction allows phagocytosis via macrophages.
IMMUNE CHECKPOINTS
Human CD47-blocking monoclonal antibodies were proven to be efficacious against solid and hematological malignancies.
More research needs to be done on combination therapy with CD47-SIRPa blockade agents.
Targeting CD47 as a cancer therapeutic strategy Folkes et al.
Macrophages are able to target cancer cells through calreticulin (CRT), an endoplasmic reticulum protein [16] . CRT activates Toll-like receptor pathways within macrophages causing phosphorylation of Bruton's tyrosine kinase [16] . This results in the expression of CRT on the surface of macrophages, which activates an anti-CD47-mediated process called programmed cell removal (PrCR) [16] . PrCR is the mechanism by which macrophages kill malignant cells via phagocytosis and intracellular degradation [ þ memory T-cell phenotype [19] . In addition to malignant T cells are the presence of nonmalignant immune cells, including CD8
þ tumor-infiltrating T cells, Tregs, dendritic cell, macrophages and mast cells [19] . Dendritic cell subsets are found in cutaneous and mucosal surfaces in both inflammatory and noninflammatory states [18 && ]. In typical CTCL tumor lesions, the number of mast cells is increased and particularly prominent at the lymphoma margins [19] . Higher mast cells were found in those with progressing disease or advanced/tumor stages [19] . In early stage mycosis fungoides, the infiltrate consists of few malignant T cells, nonmalignant Th1 cells and CD8 þ tumor-infiltrating T cells [19] . Higher densities of CD8 þ tumor-infiltrating T cells, FOXP3 þ and Tregs have been correlated with an improved survival rate in CTCL [19] .
T [23] observed that the number of CD163 (þ) cells in skin lesions of CTCL, atopic dermatitis or psoriasis was significantly larger than in normal controls. Another study demonstrated that the numbers of CD163 (þ) or CD68 (þ) cells in patients with CTCL increased as more neoplastic T cells were found in the infiltrate, and their number decreased after treatment with topical steroid and ultraviolet light [19] . TAMs can also express programmed cell death protein 1 (PD-1), an immune checkpoint receptor [24 && ]. TAMs expressing a M2 phenotype tend to express PD-1, whereas the M1 population is generally PD-1 negative [24 && ]. M2 PD-1 þ TAMs may accumulate over time in the tumor microenvironment contributing to progression [24 && ].
TREATMENT OPTIONS
In various xenograft tumor models, human CD47-blocking monoclonal antibodies were proven to have excellent efficacy against solid and hematological malignancies [10 && ]. Anti-CD47 antibody therapies not only inhibit the growth of primary site tumors, but can also prevent tumor metastasis [12] . A humanized anti-CD47 antibody has been shown to penetrate the blood-brain barrier and is deemed effective against brain tumors such as medulloblastoma and pediatric glioblastoma while not displaying toxicity toward nonmalignant neural cells ]. It binds human CD47 with tight affinity and blocks the CD47-SIRPa interaction, allowing phagocytosis of primary AML and NHL cells [26] . In the report by Liu et al. [26] , Hu5F9 was found to synergize with rituximab in the elimination of NHL in xenograft models. It is proposed that Hu5F9 will be able to synergize with any antibody capable of engaging Fc receptors in order to elicit a prophagocytic signal to eliminate the tumor cells [26] . Hu5F9 was not found to induce ADCC, complement-dependent cytotoxicity or direct apoptosis on target cells [26] . However, the induction phagocytosis in an Fc-dependent manner could not be ruled out [26] .
TTI ]. In a study by Querfeld et al. [27 && ], nine adult patients with mycosis fungoides and/or Sézary syndrome were treated with intratumoral injections of TTI-621. The lesions injected were frequently biopsied in order to assess the effects of TTI-621 on the tumor microenvironment [27 && ]. It was found that the patients treated experienced not only a decrease in tumor size rapidly clinically, but also had decreased circulating Sézary cells (in those with Sézary syndrome) after a single injection [27 && ]. NanoString analysis of peripheral blood and tumor tissue before and after injections revealed upregulation of IFN-associated genes and alterations in innate immunity activation genes, confirming the role of TTI-621 as an innate immune checkpoint inhibitor [27 && ]. Therefore, direct antitumoral injection of TTI-621 elicits both local and systemic antitumoral activity [27 && ]. Of note, TTI-621 was well tolerated in all nine patients with fatigue, chills and decreased appetite being the main treatment-related adverse effects [27 && ]. An important difference between TTI-621 and Hu5F9-G4 is the incidence of anemia and thrombocytopenia, which has been proven to be higher with Hu5F9-G4 administration [ ]. Rituximab, an anti-CD20 antibody, is a standard therapy for many CD20-positive B-cell lymphomas [11, 28] . It alone is not curative in majority of B-cell NHL patients; however, it has significantly improved long-term survival when combined with conventional chemotherapy [11, 28] . Synergistic effects were observed between anti-CD47 antibody and rituximab through both Fc receptor-dependent and Fc receptor-independent mechanisms, both leading to the stimulation of macrophage-mediated phagocytosis [11] . Trastuzumab and cetuximab (antibodies that target molecules Her2/Neu and EGFR on the cancer cell, respectively) can interact with the Fc receptor on macrophages as well to induce ADCC and further enhance anti-CD47 antibody phagocytosis. Anti-CD47 in combination with interferon-a can also provide therapeutic effects to NHL patients. A recent study by Akilov [29 && ] showed some promising results after administration of PEGylated interferon-a2a was found to work synergistically with TTI-621. In the described patient with Sézary syndrome, PEGylated interferon-a2a was given 7 days after TTI-621, which demonstrated a decrease in symptoms and leukemic burden [29 && ]. SIRPa variants should also be considered for universal immunotherapeutic adjuvants, as these have proved to increase phagocytosis in vitro and enhance antitumor responses against cancer cells in vivo [30] .
CONCLUSION
CD47 antagonists are a relatively new focus in cancer immunotherapy with benefits targeted toward solid and hematological malignancies, atherosclerosis and fibrotic diseases. More specifically, anti-CD47 antibodies have been proven, thus far, to have therapeutic effects against the tumor microenvironment in CTCL. Intralesional TTI-621, for example, has shown a good response in patients with tumor lesions. Anti-CD47 therapies are generally well tolerated with low side-effects. In patients with mycosis fungoide, consideration should be made in finding the best modality and/or combinations with synergistic antibodies in order to favorably treat this CTCL subtype.
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